Mindblown: a blog about philosophy.

Factory Direct Blinds studied paid U.S. customer orders from 2024 through 2026 to date and found homeowners choosing function over pure decoration. Factory Direct Blinds released findings from a study of real U.S. customer orders placed between 2024 and 2026 to date, showing a clear shift in how homeowners choose custom window treatments. The analysis…

With PROVAB, travel agencies and DMCs are deploying top travel technology solutions to increase topline and profits. Provab is a leading travel tech & B2B travel booking system provider known for delivering comprehensive software solutions to travel agencies, tour operators, and online travel businesses worldwide. With a strong focus on innovation and scalability, Provab supports…

With PROVAB, travel agencies and DMCs are deploying top travel technology solutions to increase topline and profits. The demand for travel technology and aviation software is expected to grow significantly in 2026 as airlines, travel agencies, airports and flight API providers continue investing in digital transformation. Businesses are increasingly adopting advanced software solutions to automate…

DelveInsight’s, “Non Muscle Invasive Bladder Cancer Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer…

Key smart medical devices companies such as Siemens Healthineers, Stryker, Samsung Electronics Co., Ltd., GE HealthCare, Koninklijke Philips N.V., Medtronic, Abbott Laboratories, Dexcom, Inc., Boston Scientific Corporation, OMRON Corporation, Apple Inc., B. Braun, iRhythm Technologies, Inc., Fresenius Kabi AG, Vital Connect, Inc., Masimo Corporation, Insulet Corporation, Zoll Medical Corporation, ResMed, F. Hoffmann-La Roche Ltd, Ypsomed,…

DelveInsight’s, “Ischemic Stroke Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ischemic Stroke pipeline therapeutics assessment by product type, stage, route of administration, and molecule type.…

DelveInsight’s “Huntington’s Disease Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Huntington’s Disease pipeline landscape. It covers the Huntington’s Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Huntington’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule…

DelveInsight’s “Wet-AMD Pipeline Insight 2026” report provides comprehensive insights about 60+ companies and 75+ pipeline drugs in the Wet-AMD pipeline landscape. It covers the Wet-AMD Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet-AMD Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights…

DelveInsight’s “Diabetic Macular Edema Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of…

Emerging PCSK9-targeted therapies including Enlicitide decanoate (MK-0616), Lerodalcibep (LIB-003), Laroprovstat (AZD0780), and VERVE-102 are driving market growth. DelveInsight’s “PCSK9 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034” report delivers an in-depth understanding of PCSK9 inhibitors, historical and competitive landscape, as well as the PCSK9-targeted therapies market trends in the United States,…